Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 2.

Journal Article

Chowdhury, S., Abida, W., Arranz Arija, J., Daugaard, G., Fizazi, K., Gez, E., Heidenreich, A., Joly Lobbedez, F., McDermott, R., Merseburger, A. S., Piulats Rodriguez, J. M., Sautois, B., Sridhar, S., Sternberg, C. N., Watkins, S., Simmons, A., Shetty, S., Golsorkhi, A., Ryan, C. J. and Scher, H. (2017). The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Heidenreich, A., Carl, S., Feyerabend, S., Gleissner, J., Gruellich, C., Heinrich, B., Merseburger, A., Miller, K., Stenzl, A., Steuber, T., Wirth, M., Watkins, S., Simmons, A., Go, J., Golsorkhi, T., Abida, W. and Scher, H. I. (2018). TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD). Oncol. Res. Treat., 41. S. 75 - 76. BASEL: KARGER. ISSN 2296-5262

This list was generated on Mon Jul 22 17:34:09 2024 CEST.